Internal Medicine, Hematology & Oncology · Asheville, NC
NPI
1811005374
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
6
Hospital affiliations
551 Brevard Rd
Asheville, NC, 28806
Phone (828) 212-7021
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.5M
135,487 services
Medicare patients, 2024
816
Average age 75
Drug cost, 2024
$3.6M
1,402 prescriptions
Company payments, 2025
$1,443
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Martin Palmeri was code J9299 (injection, nivolumab, 1 mg), 13,420 times for 12 patients. In total Martin Palmeri billed 135,487 services in 159 codes, and Medicare paid $3.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 13,420 | 12 | $24.53 | $329K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 11,522 | 16 | $0.06 | $645 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,300 | 17 | $44.72 | $505K |
| J0185 Injection, aprepitant, 1 mg | Office | 10,140 | 36 | $1.35 | $14K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 9,360 | 16 | $39.44 | $369K |
| Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 1,910 | 11 | $45.95 | $88K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 1,770 | 11 | $31.63 | $56K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,700 | 16 | $0.11 | $180 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,522 | 60 | $0.09 | $135 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,500 | 15 | $15.79 | $24K |
| 85025 Blood Count | Office | 1,220 | 544 | $7.60 | $9,270 |
| 36415 Venipuncture Blood Collection | Office | 1,002 | 503 | $8.63 | $8,650 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 960 | 47 | $0.73 | $696 |
| J9041 Injection, bortezomib, 0.1 mg | Office | 910 | 15 | $1.41 | $1,285 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 852 | 21 | $0.07 | $62.33 |
By year: 2022 $2.0M for 104,252 services; 2023 $2.2M for 115,353 services; 2024 $3.5M for 135,487 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,220 | 544 | $7.60 | $9,270 |
| 36415 Venipuncture Blood Collection | 1,002 | 503 | $8.63 | $8,650 |
| 81002 Clinical Chemistry | 59 | 24 | $3.41 | $201 |
| 85045 Blood Count | 14 | 14 | $3.91 | $54.74 |
Medicare prescription drug claims, 2024
In 2024, the drug Martin Palmeri prescribed most often to Medicare patients was Anastrozole, with 93 prescriptions and refills. In total Martin Palmeri wrote 1,402 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 93 | 199 | 26 | $1,602 |
| Prednisone Generic | 86 | 90 | 18 | $252 |
| Eliquis Apixaban | 82 | 83 | 15 | $48K |
| Ondansetron Odt Ondansetron | 59 | 59 | 39 | $1,151 |
| Levothyroxine Sodium Generic | 50 | 94 | 13 | $160 |
| Abiraterone Acetate Generic | 47 | 47 | Under 11 | $279K |
| Synthroid Levothyroxine Sodium | 45 | 51 | Under 11 | $2,282 |
| Mirtazapine Generic | 37 | 46 | Under 11 | $945 |
| Pomalyst Pomalidomide | 34 | 34 | Under 11 | $763K |
| Escitalopram Oxalate Generic | 32 | 53 | Under 11 | $324 |
| Trazimera Trastuzumab-Qyyp | 28 | 28 | Under 11 | $122K |
| Pantoprazole Sodium Generic | 28 | 44 | Under 11 | $152 |
| Revlimid Lenalidomide | 26 | 26 | Under 11 | $453K |
| Ondansetron Hcl Generic | 26 | 26 | 11 | $210 |
| Prochlorperazine Maleate Generic | 25 | 25 | 20 | $282 |
Brand drugs: 447 claims; generic drugs: 955 claims; opioid claims: 48.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Martin Palmeri $1,443 ($1,443 in general payments such as food, travel and fees) from 27 companies. The largest payer was Janssen Biotech, Inc. with $244.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 10 | $244 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $174 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $99.8 |
| Abbvie Inc. ABBV | 4 | $93.78 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $86.61 |
| Pfizer Inc. PFE | 4 | $79.75 |
| Array Biopharma Inc PFE | 4 | $78.66 |
| BeOne Medicines USA, Inc. ONC | 3 | $63.83 |
| Lilly USA, LLC LLY | 3 | $56.16 |
| Genentech USA, Inc. ROG.SW | 2 | $51.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.